Probiodrug

Probiodrug is a private biopharmaceutical company focused on developing innovative small molecule drugs. Founded in 1997, the company has raised $52 million in private equity funding. Additionally, it has generated over $50 million in revenue and carries no debt. Probiodrug has pioneered an industrialized approach to making innovative targeted drugs accessible. Its core expertise lies in elucidating the structure, biochemistry, biology, and pathophysiology of modulating peptides and enzyme-modified specific proteins and pathway activities.